Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2020 | Impact of COVID-19 on the management of MDS

Rami Komrokji • 27 Aug 2020
SOHO 2020
Myelodysplastic Syndromes

Rami Komrokji, MD, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, discusses the impact of the COVID-19 pandemic on the treatment and management of patients with myelodysplastic syndrome (MDS). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Rami Komrokji

4:00
Real-world data on the efficacy of luspatercept in LR-MDS
Rami Komrokji • 19 Dec 2022
3:35
Analysis from MOST: disease progression and leukemic transformation in lower-risk myelofibrosis
Rami Komrokji • 19 Dec 2022
4:21
Evaluating luspatercept in combination with ESAs for the treatment of anemia in LR-MDS
Rami Komrokji • 19 Dec 2022
3:12
Prolonged & continuous transfusion independence after imetelstat treatment in the IMerge trial
Rami Komrokji • 19 Dec 2022

Related Videos

2:08
Somatic mutations in MDS as targets for therapy
Valeria Santini • 25 Sep 2018
2:35
Stapled peptide ALRN-6924 for AML and MDS
David Sallman • 17 Dec 2018
4:55
Checkpoint inhibitor combination approaches for AML/MDS: an update
Naval Daver • 14 Mar 2019
3:24
Data for APR-246 and azacitidine in patients with mTP53 MDS and AML
David Sallman • 17 Dec 2018
The content of VJHemOnc is intended for healthcare professionals